LCM
EVFM

Laurion Capital Management’s Evofem Biosciences, Inc. Common Stock EVFM Stock Holding History

Laurion Capital Management’s Portfolio EVFM Stock Details EVFM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-26,667
Closed -$700K – 1037
2021
Q1 		$700K Buy
+26,667
New +$1.21M ﹤0.01% 542

Other funds holding EVFM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
FWSM
First Wilshire Securities Management Pasadena, California $444M AUM 42.88% 1-Year Est. Return

Laurion Capital Management's EVFM Position: Q2 2021 in Review

Laurion Capital Management sold out of Evofem Biosciences, Inc. Common Stock (EVFM) in Q2 2021, closing a stake of 26,667 shares — an estimated $700K sold.

Laurion Capital Management first reported a position in EVFM in Q1 2021 and held it in 1 quarter. The position peaked at $700K in Q1 2021. 81 funds tracked by Wall St. Rank hold EVFM as of Q2 2021.

  • Laurion Capital Management reported no remaining Evofem Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Laurion Capital Management sold 26,667 Evofem Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $700K.
  • Laurion Capital Management first reported a position in Evofem Biosciences, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Laurion Capital Management's Evofem Biosciences, Inc. Common Stock position peaked at $700K in Q1 2021.
  • 81 funds tracked by Wall St. Rank held Evofem Biosciences, Inc. Common Stock as of Q2 2021.

Based on Laurion Capital Management's 13F filing for Q2 2021, filed 13 Aug 2021.